Core Insights - Abivax announced the presentation of seven scientific abstracts regarding its lead drug candidate, obefazimod, at the 2025 European Crohn's and Colitis Organization Annual Congress [1][2] - Obefazimod is in clinical development for treating moderately to severely active ulcerative colitis [1][5] Presentation Details - The abstracts will cover various aspects of obefazimod, including efficacy, safety, and quality of life in patients with ulcerative colitis [3][4] - Notable presentations include an oral presentation on dose escalation and multiple poster presentations focusing on treatment impacts and safety profiles [3][4] Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapies that stabilize the immune response in chronic inflammatory diseases [5] - The company is based in France and the United States, with obefazimod currently in Phase 3 clinical trials for ulcerative colitis [5]
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress